{"id":"NCT01863758","sponsor":"Octapharma","briefTitle":"Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A","officialTitle":"Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2013-05-29","resultsPosted":"2018-01-30","lastUpdate":"2018-01-30"},"enrollment":66,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Severe Haemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Human-cl rhFVIII","otherNames":[]}],"arms":[{"label":"Human-cl rhFVIII","type":"EXPERIMENTAL"}],"summary":"To compare the number of breakthrough bleeds under tailored prophylaxis with Human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand treatment.","primaryOutcome":{"measure":"Annualized Number of Bleeding Episodes (BE) in Phase II","timeFrame":"Beginning to the end of Phase II (6 months)","effectByArm":[{"arm":"Human-cl rhFVIII","deltaMin":3.05,"sd":13.43}],"pValues":[{"comp":"OG000","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":20,"countries":["Austria","Bulgaria","Germany","Hungary","Poland","Romania","Slovakia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":66},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Tonsillitis","Back pain"]}}